PARP-inhibitors: A New Generation of Cancer Drugs

New FDA Approved PARP Inhibitor: Talzenna (Talazoparib) & Xtandi | #markscholzmd #AlexScholz #pcriПодробнее

Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel ApproachesПодробнее

PARP inhibitors A New Generation of Cancer DrugsПодробнее

What is a PARP Inhibitor? | Dana-Farber Cancer Institute | Science IllustratedПодробнее

PARP inhibitors – a cancer drug discovery story | Professor Ruth Plummer FMedSciПодробнее

PARP Inhibitors: Revolutionising Cancer TreatmentПодробнее

The Role of PARP Inhibitors in Advanced Prostate Cancer (2023)Подробнее

Seminar Clips: PARP Inhibitors and BRRCA1/2 Cancers- Susan Domchek, MD | Stanford Cancer InstituteПодробнее

PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023Подробнее

What’s New with PARP Inhibitors and Ovarian Cancer?Подробнее

Dr. Monk on Choosing Between PARP Inhibitors in Ovarian CancerПодробнее

Current perspectives from clinical trials using PARP inhibitors for prostate cancerПодробнее

Case 4: PARP Inhibitors for Treating BRCA+ Triple-Negative Breast CancerПодробнее

PARP Inhibitors for Maintenance Therapy in Ovarian CancerПодробнее

Assessing the role of PARP inhibitors and immunotherapy in ovarian cancerПодробнее

PARP inhibitors plus novel endocrine agents for patients with metastatic prostate cancerПодробнее

BRCA & PARP Inhibitors: Targeted Chemotherapy | #MarkScholzMD #AlexScholz @PCRIПодробнее

Mechanisms of PARP Inhibition: A Mode of Targeted Cancer TreatmentПодробнее

An Overview of PARP Inhibitors in Ovarian CancerПодробнее

PARP Inhibitors: 2023 UpdatesПодробнее